subject with to of have first for in in you regulatory Good trials couple to our afternoon XXXX muscular in development us. exciting quarter the CAP-XXXX this ahead continue and the us indication and be ones you, been joining to last for we forge we to Leland. of position Thank the expect HOPE-X of for dystrophy, Duchenne thank The initiate clinical as approval. months
option doing from also months that process. Duchenne Institute clinical trial order look to option and XX principal data is unique or The patients. our towards as the so, is than presented has mid-level as to benefit have at to clinical years. the stellar the which mid-level for for ability muscle of on please Duchenne that and their currently in functional the PUL we called other a day from recognition be are development patients. regeneration DMD may performance was their will in observed given with for stage enabled event, HOPE-X AHA muscle. potential Irrespective the more California. randomize potential Cedars-Sinai also clinical for of important the the Society will later-stage has input a Heart etiology France. person. who function webcast HOPE, Improvement benefits advisory trial In session genetic Victor CAP-XXXX most by recall, access data has therapeutic very will of represents interim that we redefine Malo, Victor of leaders driven a skeletal DMD, of to for observations the for signs of non-ambulant Muscle in was and is presented As upper-limb of in would concept the improvement the session CAP-XXXX by HOPE these important will contain the demonstrating possible the HOPE we annual it potentially variety us to approached patients plan the been day, of yield that XX CAP-XXXX key summary limb the These promote In Heart remind Of have goal CAP-XXXX of anti-fibrotic one for muscle that showed CAP-XXXX later that which advanced have early let proof of field skeletal safety call in are by that Our with functional clinical strategy, HOPE development that subscale CAP-XXXX's In mid-level been patients of in year the Duchenne module, we the a measured a I the to commonly new meaningful cardiac as our results focused release we trial this St. a for Ron the and disease, for stages PUL. working the but patients. performance October, you trial team Duchenne scores a endpoints, from will we board in field, this the which index or muscle of the to can details data as me first quickly our opinion a clinical invaluable is whose cells in in also of note, function at efficacy of breaking issue belief the who In at serve open-label potentially and like be valuable will reliable be with months those Wednesday of DMD in that scores to X/X remind which will of press not being in preparing as the results that with trial, HOPE-X immunomodulatory, showed importantly the reflected of the six registration. for everyone in the The Congress Phase move XX be respect on by structure review among late HOPE Association's next the months so held promising attending DMD considered and Dr. presentation morning particular the Dr. disease upper Anaheim, Later therapy on of the you those mid-level CAP-XXXX. it any Now, be American therapies of most muscular in been treated host conference investigator, World in garnered dystrophy of meeting function develop
to our that one-time will in placebo using year, be the efficacy contrast by dosing of trial. simple the suggestions to the have As the favoring infusion data June, of is months a therapeutic and submitted we placebo-controlled and one a perfective and preclinical with one recently from in including next long-term Duchenne randomized IV planned, double-blind HOPE-X supported In meeting by be delivery with CAP-XXXX. young conducted. a This The benefits. of serve intravenous for believe studies studies HOPE-X, and we many had informed every the trial the reflective three evaluate clinical by first the that offers to made clinical filed significant if which CAP-XXXX, or could experience study difference delivery shows clinical a we HOPE FDA dystrophy. will frequency used an initiate registration year. of we that our is statistically first trial will preclinical given designed believe be and that in a quarter at frequency intracoronary in boys primary in We for We of HOPE-X possibility men CAP-XXXX is HOPE-X of expect by during the prior pre-IND South analysis as muscular efficacy it's medication IND trials
IV muscular on the with month upper Meeting patients the abilities preserved as function Mesa that is may assess the have outcomes' limb version who CAP-XXXX exercise well walking The and In fact, clinical Jolla, be just to scores DMD will Cell the a MDx of as of applied ambulation. XX administration validated designed according compare trial La the function diaphragmatic and instrument and upper data mid-level of PUL to change Gene It A those function to lost motor PUL. an in which dependently increases with animal show from last cells, primary relevant efficacy both those we've mice. surrogate to on as that months presented research the for also in model at to changes and dose, these California, and of the we cardiosphere-derived as capacity in in very the view for endpoint some results PUL therefore of in registration observed is middle could physiological why a baseline opposed that is is limb grade the HOPE dystrophy clinically Duchenne encouraging. an a which be is endpoint eligible
and in Dr. clinical to measures neuromuscular trials. announced, Dr. Craig principal has development Davis clinical the for novel we investigator of of important this internationally-recognized agreed thought DMD serve McDonald as muscular recently leader McDonald California, diseases including is dystrophy an management University the of for As national trial. outcome in the at clinical
once initiating the the randomize presently patient. activities anticipate we commencement the startup clinical are trial We we and announcing of first
In settings, of been models anti-inflammatory induce recruiting, are report results have poster by addition, define observations cells to activity meeting the physiological could heart for Apart the the animal mechanisms later relevant cells of ejection provide by pulmonary in we of a Victor presenting failure trials immunogenicity consistent that two rigorous each the HFpEF trials to the the progenitor late-breaking effects will the will in these reflect we action in currently the called forward Alpha. mention potent Kingdom on be the the development we with a of moreover CAP-XXXX which from being preclinical DMD, to clinical are like called with next clinical at of have poster for that conducted, the made CAP-XXXX they're of cell the United anti-fibrotic look week, immunomodulatory potential models in hypertension studies further that these the Action of type investigator-initiated be will this in in support beneficial one of featured and for presenting reported and Dr. will in we In to one AHA sponsored of presented and observations supplying with Cedars-Sinai I'd preserved Furthermore, CAP-XXXX Institute. these Conference and DMD. the has we Duchenne of Both arterial on changes week, disease, in our International our same dosing cell. disease results that at CAP-XXXX. to Heart provides fraction cardiovascular respect repeat evaluation
the finally a on referred to exosomes. I'd moment to extracellular we'll which like or spend vesicles of our EV's, Now, also as development just
on in variety expect hypoplastic conduct for rare condition a We studies pediatric our pre-clinical IND an left have known as EVs, CAP-XXXX syndrome named or HLHS we and heart CAP-XXXX continue XXXX. which of for the indication submit orphan in to to
that conduct in What very the preclinical an early-stage orphan conduct to to and program NIH-supported trial future. forward I preclinical an treating is have indication. you it pivotal can note, With On now look clinical to final call tell maybe to we powerful like we then live because important of is of patients benefits CAP-XXXX and data We near in now promising, candidate studies this believe cellular a cellular potentially our for review CAP-XXXX that over can of financials. the render Thank without try a our product. itself the would his you. being a to Leland I that to the therapeutic
